Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating Biomarkers
ABSTRACT Background To assess whether changes in TP53 mutations and copy number alterations (CNA) in plasma circulating tumor DNA (ctDNA) can predict treatment response and prognosis in platinum‐resistant recurrent ovarian cancer (PROC) patients. Methods Fifty‐seven PROC patients were recruited. For...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Cancer Innovation |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cai2.70014 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849427836866134016 |
|---|---|
| author | Haixia Cheng Guangwen Yuan Leilei Liang Tiantian Wang Jiarun Zhu Hongying Yang Zhendiao Zhou Pei Wang Qianqian Song Yuchen Jiao Mei Liu Lingying Wu |
| author_facet | Haixia Cheng Guangwen Yuan Leilei Liang Tiantian Wang Jiarun Zhu Hongying Yang Zhendiao Zhou Pei Wang Qianqian Song Yuchen Jiao Mei Liu Lingying Wu |
| author_sort | Haixia Cheng |
| collection | DOAJ |
| description | ABSTRACT Background To assess whether changes in TP53 mutations and copy number alterations (CNA) in plasma circulating tumor DNA (ctDNA) can predict treatment response and prognosis in platinum‐resistant recurrent ovarian cancer (PROC) patients. Methods Fifty‐seven PROC patients were recruited. Forty‐three patients with matched tumor and plasma samples were analyzed via both a tumor‐informed ctDNA assay (TICA) and a tumor‐uninformed ctDNA assay (TUCA) profiling TP53 mutations and CNA. The TUCA algorithm was optimized based on TICA results. Fourteen patients without matched tumor tissues were used just for TUCA analysis. Results A ctDNA decrease of ≥ 80% from baseline or ctDNA negativity during treatment detected by the TICA (defined as favorable TICA changes) strategy before the third cycle predicted the best overall response, with 81.8% sensitivity and 84.6% specificity. The TUCA strategy was defined as a combination of TP53 mutations and CNA changes. A favorable TUCA change before the third cycle predicted the best overall response, with 90.0% sensitivity and 63.2% specificity. In 12 patients without clinical benefit, the median lead time to detect drug resistance from TUCA to the Response Evaluation Criteria in Solid Tumors was 86.0 days. Patients with favorable ctDNA changes (n = 15) detected by TUCA before the third cycle had a median progression‐free survival of 9.2 months, versus 3.6 months in those without (n = 34) (HR: 2.88; 95% CI 1.56–5.30; log‐rank p = 0.0008). Conclusions Similar to TICA, ctDNA changes detected by TUCA combined with TP53 mutations and CNA could predict treatment response and prognosis in PROC patients without requiring tumor tissues. |
| format | Article |
| id | doaj-art-4397fc72133446a6bf1ce3d1020fa93d |
| institution | Kabale University |
| issn | 2770-9191 2770-9183 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Innovation |
| spelling | doaj-art-4397fc72133446a6bf1ce3d1020fa93d2025-08-20T03:28:54ZengWileyCancer Innovation2770-91912770-91832025-08-0144n/an/a10.1002/cai2.70014Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating BiomarkersHaixia Cheng0Guangwen Yuan1Leilei Liang2Tiantian Wang3Jiarun Zhu4Hongying Yang5Zhendiao Zhou6Pei Wang7Qianqian Song8Yuchen Jiao9Mei Liu10Lingying Wu11Laboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Gynecologic Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Gynecologic Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Gynecologic Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaLaboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaPeking University Cancer Hospital Yunnan Hospital/Yunnan Provincial Cancer Hospital/The Third Affiliated Hospital of Kunming Medical University Kunming Yunnan ChinaLaboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaLaboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaLaboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaLaboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaLaboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Gynecologic Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaABSTRACT Background To assess whether changes in TP53 mutations and copy number alterations (CNA) in plasma circulating tumor DNA (ctDNA) can predict treatment response and prognosis in platinum‐resistant recurrent ovarian cancer (PROC) patients. Methods Fifty‐seven PROC patients were recruited. Forty‐three patients with matched tumor and plasma samples were analyzed via both a tumor‐informed ctDNA assay (TICA) and a tumor‐uninformed ctDNA assay (TUCA) profiling TP53 mutations and CNA. The TUCA algorithm was optimized based on TICA results. Fourteen patients without matched tumor tissues were used just for TUCA analysis. Results A ctDNA decrease of ≥ 80% from baseline or ctDNA negativity during treatment detected by the TICA (defined as favorable TICA changes) strategy before the third cycle predicted the best overall response, with 81.8% sensitivity and 84.6% specificity. The TUCA strategy was defined as a combination of TP53 mutations and CNA changes. A favorable TUCA change before the third cycle predicted the best overall response, with 90.0% sensitivity and 63.2% specificity. In 12 patients without clinical benefit, the median lead time to detect drug resistance from TUCA to the Response Evaluation Criteria in Solid Tumors was 86.0 days. Patients with favorable ctDNA changes (n = 15) detected by TUCA before the third cycle had a median progression‐free survival of 9.2 months, versus 3.6 months in those without (n = 34) (HR: 2.88; 95% CI 1.56–5.30; log‐rank p = 0.0008). Conclusions Similar to TICA, ctDNA changes detected by TUCA combined with TP53 mutations and CNA could predict treatment response and prognosis in PROC patients without requiring tumor tissues.https://doi.org/10.1002/cai2.70014circulating tumor DNAcopy number alterationsovarian cancerTP53 mutations |
| spellingShingle | Haixia Cheng Guangwen Yuan Leilei Liang Tiantian Wang Jiarun Zhu Hongying Yang Zhendiao Zhou Pei Wang Qianqian Song Yuchen Jiao Mei Liu Lingying Wu Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating Biomarkers Cancer Innovation circulating tumor DNA copy number alterations ovarian cancer TP53 mutations |
| title | Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating Biomarkers |
| title_full | Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating Biomarkers |
| title_fullStr | Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating Biomarkers |
| title_full_unstemmed | Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating Biomarkers |
| title_short | Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating Biomarkers |
| title_sort | prediction of therapeutic response and prognosis in ovarian cancer patients with plasma circulating biomarkers |
| topic | circulating tumor DNA copy number alterations ovarian cancer TP53 mutations |
| url | https://doi.org/10.1002/cai2.70014 |
| work_keys_str_mv | AT haixiacheng predictionoftherapeuticresponseandprognosisinovariancancerpatientswithplasmacirculatingbiomarkers AT guangwenyuan predictionoftherapeuticresponseandprognosisinovariancancerpatientswithplasmacirculatingbiomarkers AT leileiliang predictionoftherapeuticresponseandprognosisinovariancancerpatientswithplasmacirculatingbiomarkers AT tiantianwang predictionoftherapeuticresponseandprognosisinovariancancerpatientswithplasmacirculatingbiomarkers AT jiarunzhu predictionoftherapeuticresponseandprognosisinovariancancerpatientswithplasmacirculatingbiomarkers AT hongyingyang predictionoftherapeuticresponseandprognosisinovariancancerpatientswithplasmacirculatingbiomarkers AT zhendiaozhou predictionoftherapeuticresponseandprognosisinovariancancerpatientswithplasmacirculatingbiomarkers AT peiwang predictionoftherapeuticresponseandprognosisinovariancancerpatientswithplasmacirculatingbiomarkers AT qianqiansong predictionoftherapeuticresponseandprognosisinovariancancerpatientswithplasmacirculatingbiomarkers AT yuchenjiao predictionoftherapeuticresponseandprognosisinovariancancerpatientswithplasmacirculatingbiomarkers AT meiliu predictionoftherapeuticresponseandprognosisinovariancancerpatientswithplasmacirculatingbiomarkers AT lingyingwu predictionoftherapeuticresponseandprognosisinovariancancerpatientswithplasmacirculatingbiomarkers |